Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

To the Editor: The window for postexposure prophylaxis against Covid-19 is narrow. 1-3 Therapy that is initiated up to 4 days after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is early treatment, not postexposure prophylaxis. The trial described in the article by Boulwar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2020-09, Vol.383 (11), p.1087-1089
Hauptverfasser: Avidan, Michael S, Dehbi, Hakim-Moulay, Delany-Moretlwe, Sinead, Khan, Muhammad-Shahzeb, Butler, Javed, Tekwani, Babu L, Okafor, Elizabeth C, Pastick, Katelyn A, Rajasingham, Radha
Format: Artikel
Sprache:eng
Schlagworte:
Coronaviruses
COVID-19
Hydroxychloroquine
Prophylaxis
Severe acute respiratory syndrome coronavirus 2
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1089
container_issue 11
container_start_page 1087
container_title The New England journal of medicine
container_volume 383
creator Avidan, Michael S
Dehbi, Hakim-Moulay
Delany-Moretlwe, Sinead
Khan, Muhammad-Shahzeb
Butler, Javed
Tekwani, Babu L
Okafor, Elizabeth C
Pastick, Katelyn A
Rajasingham, Radha
description To the Editor: The window for postexposure prophylaxis against Covid-19 is narrow. 1-3 Therapy that is initiated up to 4 days after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is early treatment, not postexposure prophylaxis. The trial described in the article by Boulware et al. (published online on June 3 at NEJM.org) 4 was therefore largely about the prevention of symptoms in persons who may already have been infected. The trial was designed to detect a 50% relative reduction in new cases of symptomatic Covid-19; this estimate was overly optimistic. The trial was not powered to detect an important, but . . .
doi_str_mv 10.1056/NEJMc2023617
format Article
fullrecord <record><control><sourceid>proquest_mms_n</sourceid><recordid>TN_cdi_proquest_journals_2441297747</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2441297747</sourcerecordid><originalsourceid>FETCH-LOGICAL-m142t-500ab323b46095b6a249bba8941edfe2d75f6b1d1a26cf00faea46dcdb7da0813</originalsourceid><addsrcrecordid>eNpNkDFPwzAUhC0EEqWw8QMiwRp4z3bsWkwoKhRUoAPMlh3baqOmDnGC2n9PqzJwyy2f7k5HyDXCHUIh7t-nr28VBcoEyhMywoKxnHMQp2QEQCc5l4qdk4uUatgLuRqRh9nOdXG7q5br2MXvYbXxmUnZIqbeb9uYhs5niy62y93abFcpC7HLyvizcjmqS3IWzDr5qz8fk6-n6Wc5y-cfzy_l4zxvkNM-LwCMZZRZLkAVVhjKlbVmojh6Fzx1sgjCokNDRRUAgvGGC1c5K52BCbIxuTnmtoeFPvW6jkO32VdqyjlSJSWXe-r2SDVN0htfNxpBH27R_29hv3DFVLA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2441297747</pqid></control><display><type>article</type><title>Hydroxychloroquine as Postexposure Prophylaxis for Covid-19</title><source>New England Journal of Medicine Current</source><source>ProQuest Central UK/Ireland</source><source>EZB Electronic Journals Library</source><creator>Avidan, Michael S ; Dehbi, Hakim-Moulay ; Delany-Moretlwe, Sinead ; Khan, Muhammad-Shahzeb ; Butler, Javed ; Tekwani, Babu L ; Okafor, Elizabeth C ; Pastick, Katelyn A ; Rajasingham, Radha</creator><creatorcontrib>Avidan, Michael S ; Dehbi, Hakim-Moulay ; Delany-Moretlwe, Sinead ; Khan, Muhammad-Shahzeb ; Butler, Javed ; Tekwani, Babu L ; Okafor, Elizabeth C ; Pastick, Katelyn A ; Rajasingham, Radha</creatorcontrib><description>To the Editor: The window for postexposure prophylaxis against Covid-19 is narrow. 1-3 Therapy that is initiated up to 4 days after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is early treatment, not postexposure prophylaxis. The trial described in the article by Boulware et al. (published online on June 3 at NEJM.org) 4 was therefore largely about the prevention of symptoms in persons who may already have been infected. The trial was designed to detect a 50% relative reduction in new cases of symptomatic Covid-19; this estimate was overly optimistic. The trial was not powered to detect an important, but . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMc2023617</identifier><language>eng</language><publisher>Boston: Massachusetts Medical Society</publisher><subject>Coronaviruses ; COVID-19 ; Hydroxychloroquine ; Prophylaxis ; Severe acute respiratory syndrome coronavirus 2</subject><ispartof>The New England journal of medicine, 2020-09, Vol.383 (11), p.1087-1089</ispartof><rights>Copyright © 2020 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMc2023617$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2441297747?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,2760,26103,27924,27925,52382,54064,64385,64389,72341</link.rule.ids></links><search><creatorcontrib>Avidan, Michael S</creatorcontrib><creatorcontrib>Dehbi, Hakim-Moulay</creatorcontrib><creatorcontrib>Delany-Moretlwe, Sinead</creatorcontrib><creatorcontrib>Khan, Muhammad-Shahzeb</creatorcontrib><creatorcontrib>Butler, Javed</creatorcontrib><creatorcontrib>Tekwani, Babu L</creatorcontrib><creatorcontrib>Okafor, Elizabeth C</creatorcontrib><creatorcontrib>Pastick, Katelyn A</creatorcontrib><creatorcontrib>Rajasingham, Radha</creatorcontrib><title>Hydroxychloroquine as Postexposure Prophylaxis for Covid-19</title><title>The New England journal of medicine</title><description>To the Editor: The window for postexposure prophylaxis against Covid-19 is narrow. 1-3 Therapy that is initiated up to 4 days after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is early treatment, not postexposure prophylaxis. The trial described in the article by Boulware et al. (published online on June 3 at NEJM.org) 4 was therefore largely about the prevention of symptoms in persons who may already have been infected. The trial was designed to detect a 50% relative reduction in new cases of symptomatic Covid-19; this estimate was overly optimistic. The trial was not powered to detect an important, but . . .</description><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Hydroxychloroquine</subject><subject>Prophylaxis</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpNkDFPwzAUhC0EEqWw8QMiwRp4z3bsWkwoKhRUoAPMlh3baqOmDnGC2n9PqzJwyy2f7k5HyDXCHUIh7t-nr28VBcoEyhMywoKxnHMQp2QEQCc5l4qdk4uUatgLuRqRh9nOdXG7q5br2MXvYbXxmUnZIqbeb9uYhs5niy62y93abFcpC7HLyvizcjmqS3IWzDr5qz8fk6-n6Wc5y-cfzy_l4zxvkNM-LwCMZZRZLkAVVhjKlbVmojh6Fzx1sgjCokNDRRUAgvGGC1c5K52BCbIxuTnmtoeFPvW6jkO32VdqyjlSJSWXe-r2SDVN0htfNxpBH27R_29hv3DFVLA</recordid><startdate>20200910</startdate><enddate>20200910</enddate><creator>Avidan, Michael S</creator><creator>Dehbi, Hakim-Moulay</creator><creator>Delany-Moretlwe, Sinead</creator><creator>Khan, Muhammad-Shahzeb</creator><creator>Butler, Javed</creator><creator>Tekwani, Babu L</creator><creator>Okafor, Elizabeth C</creator><creator>Pastick, Katelyn A</creator><creator>Rajasingham, Radha</creator><general>Massachusetts Medical Society</general><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20200910</creationdate><title>Hydroxychloroquine as Postexposure Prophylaxis for Covid-19</title><author>Avidan, Michael S ; Dehbi, Hakim-Moulay ; Delany-Moretlwe, Sinead ; Khan, Muhammad-Shahzeb ; Butler, Javed ; Tekwani, Babu L ; Okafor, Elizabeth C ; Pastick, Katelyn A ; Rajasingham, Radha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-m142t-500ab323b46095b6a249bba8941edfe2d75f6b1d1a26cf00faea46dcdb7da0813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Hydroxychloroquine</topic><topic>Prophylaxis</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Avidan, Michael S</creatorcontrib><creatorcontrib>Dehbi, Hakim-Moulay</creatorcontrib><creatorcontrib>Delany-Moretlwe, Sinead</creatorcontrib><creatorcontrib>Khan, Muhammad-Shahzeb</creatorcontrib><creatorcontrib>Butler, Javed</creatorcontrib><creatorcontrib>Tekwani, Babu L</creatorcontrib><creatorcontrib>Okafor, Elizabeth C</creatorcontrib><creatorcontrib>Pastick, Katelyn A</creatorcontrib><creatorcontrib>Rajasingham, Radha</creatorcontrib><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing &amp; Allied Health Database</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>New England Journal of Medicine</collection><collection>Biological Sciences</collection><collection>ProQuest Consumer Health Database</collection><collection>ProQuest Healthcare Administration Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>Psychology Database</collection><collection>ProQuest Research Library</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Avidan, Michael S</au><au>Dehbi, Hakim-Moulay</au><au>Delany-Moretlwe, Sinead</au><au>Khan, Muhammad-Shahzeb</au><au>Butler, Javed</au><au>Tekwani, Babu L</au><au>Okafor, Elizabeth C</au><au>Pastick, Katelyn A</au><au>Rajasingham, Radha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hydroxychloroquine as Postexposure Prophylaxis for Covid-19</atitle><jtitle>The New England journal of medicine</jtitle><date>2020-09-10</date><risdate>2020</risdate><volume>383</volume><issue>11</issue><spage>1087</spage><epage>1089</epage><pages>1087-1089</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>To the Editor: The window for postexposure prophylaxis against Covid-19 is narrow. 1-3 Therapy that is initiated up to 4 days after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is early treatment, not postexposure prophylaxis. The trial described in the article by Boulware et al. (published online on June 3 at NEJM.org) 4 was therefore largely about the prevention of symptoms in persons who may already have been infected. The trial was designed to detect a 50% relative reduction in new cases of symptomatic Covid-19; this estimate was overly optimistic. The trial was not powered to detect an important, but . . .</abstract><cop>Boston</cop><pub>Massachusetts Medical Society</pub><doi>10.1056/NEJMc2023617</doi><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0028-4793
ispartof The New England journal of medicine, 2020-09, Vol.383 (11), p.1087-1089
issn 0028-4793
1533-4406
language eng
recordid cdi_proquest_journals_2441297747
source New England Journal of Medicine Current; ProQuest Central UK/Ireland; EZB Electronic Journals Library
subjects Coronaviruses
COVID-19
Hydroxychloroquine
Prophylaxis
Severe acute respiratory syndrome coronavirus 2
title Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T16%3A05%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_mms_n&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hydroxychloroquine%20as%20Postexposure%20Prophylaxis%20for%20Covid-19&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Avidan,%20Michael%20S&rft.date=2020-09-10&rft.volume=383&rft.issue=11&rft.spage=1087&rft.epage=1089&rft.pages=1087-1089&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMc2023617&rft_dat=%3Cproquest_mms_n%3E2441297747%3C/proquest_mms_n%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2441297747&rft_id=info:pmid/&rfr_iscdi=true